CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
29 hedge funds and large institutions have $3.84M invested in CASI Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 5 closing their positions.
20% more capital invested
Capital invested by funds: $3.21M → $3.84M (+$629K)
3% less funds holding
Funds holding: 30 → 29 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$364K |
| 2 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
+$22.6K |
| 3 |
Renaissance Technologies
New York
|
+$10.5K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.48K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$6.47K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$25K |
| 2 |
WSC
Wellington Shields & Co
New York
|
-$23.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$16K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$5.92K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.5K |
CASI Hedge Fund Activity: Q2 2015 in Review
29 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q2 2015, worth a combined $3.84M — up 20% from $3.21M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CASI and 4 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 4 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $364K. The largest seller was Dimensional Fund Advisors, exiting entirely with an estimated $25K sold.
- 29 institutional investors held CASI Pharmaceuticals (CASI) as of Q2 2015, down from 30 in Q1 2015.
- Funds reported $3.84M of CASI Pharmaceuticals stock for Q2 2015, up 20% quarter-over-quarter.
- 4 funds opened new CASI Pharmaceuticals positions in Q2 2015 and 5 closed out, a net change of -1 holder.
- The largest CASI Pharmaceuticals buyer in Q2 2015 was Sabby Management, an estimated $364K added.
- The largest CASI Pharmaceuticals seller in Q2 2015 was Dimensional Fund Advisors, an estimated $25K sold.
Based on aggregated 13F filings for Q2 2015.